Abstract:
An object is to provide a semiconductor device having a memory which can efficiently improve a yield by employing a structure which facilitates the use of a spare memory cell. The semiconductor device includes a memory cell array having a memory cell and a spare memory cell, a decoder connected to the memory cell and the spare memory cell, a data holding circuit connected to the decoder, and a battery which supplies electric power to the data holding circuit. The spare memory cell operates in accordance with an output from the data holding circuit.
Abstract:
The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases.As a result of investigations with respect to novel condensed heterocyclic derivatives, the inventors have verified that a condensed pyridine compound has excellent JAK3 inhibitory activity, thereby completing the present invention.More specifically, it has been verified that since the compound according to the present invention has inhibitory activity against JAK3, the compound is useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transduction (e.g., rejection during live organ/tissue transplantation, autoimmune diseases, asthma, atopic dermatitis, rheumatism, psoriasis and atherosclerotic disease), or diseases caused by abnormal cytokine signal transduction (e.g., cancer and leukemia).
Abstract:
A compound of the formula (I): U-V-W-X-Y-Z (I) wherein U is lower alkyl; V is —CONH— or —NR1CO— wherein R1 is a hydrogen or lower alkyl; W is a bond or lower alkylene; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond or lower alkylene; and Z is a group of the formula: wherein R2 is a group of the formula: -A-B-D-E-F-G wherein A is a bond or lower alkylene; B is a bond, —NH— or D is a bond, —CS— or —CO—; E is a bond or —NH—; F is a bond, —CO—, —O— or —SO2—; and G is lower alkyl, optionally protected amino, —OH, phenyl, R3 is lower alkyl, provided that when Z is a group of the formula: then G should not be amino, when Z is a group of the formula: then G should not be when Z is a group of the formula: and G is optionally protected amino, then D should be —CS—, or then A should be lower alkylene, B or E should be —NH— and F should be —CO—; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.
Abstract:
An image acquiring apparatus is made up of a macro image acquiring unit 20 used to acquire a macro image of each of a plurality of samples S, and a control unit 60 including a macro image acquisition control unit used to control a macro image acquiring operation and an image pickup condition setting unit used to set an image pickup condition for a micro image of the sample S with reference to the macro image. The control unit 60 includes a session managing unit used to define a session in accordance with a sample group consisting of the samples S and to manage a data group including data of the macro image and the image pickup condition as session data associated with the sample group for each session. According to this structure, it is possible to realize an image acquiring apparatus, an image acquiring method, and an image acquiring program capable of suitably managing image acquisition processing performed to acquire an image of each of a plurality of samples.
Abstract:
Compounds of formula (I) where R1 is hydrogen; R2 is nitro, cyano or halo(lower)alkyl; R3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R4 is a group CR6R7R8 wherein R6 and R7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R8 is hydrogen; its prodrug and a salt thereof.
Abstract:
This invention relates to a compound of the formula: ##STR1## wherein Z is a group of the formula: ##STR2## in which X.sup.1 is N or C--R.sup.1,X.sup.2 is N or C--R.sup.9,X.sup.3 is N or C--R.sup.2,R.sup.1 is lower alkyl,R.sup.2 is hydrogen, lower alkyl, etc.,R.sup.9 is hydrogen or lower alkyl,R.sup.3 is halogen, etc.,R.sup.4 is halogen, etc.,R.sup.5 is a group of the formula: ##STR3## A is lower alkylene, and Y is O, etc.,and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods to using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.
Abstract:
A compound of the formula: ##STR1## or its salt is prepared by reacting a compound of the formula: ##STR2## with a compound of the formula: ##STR3## Wherein the variables are all defined in claim 1.
Abstract:
Thermoplastic resin composition comprising the following components A and B is presented which improves the compatibility of component resins, to achieve a thermoplastic resin having excellent molding property and mechanical strength:A. 90 to 10 wt % of a polyolefin resin containing a substituted silyl group represented by general formula;--SiR.sub.n Y.sub.3-n (wherein, R is aliphatic hydrocarbon group; Y is hydrolyzable group or hydroxyl group; n represents 0, 1 or 2), andB. 10 to 90 wt % of saturated polyester resin or hydroxyalkylated polycarbonate resin or hydroxyalkylated polyphenylene ether resin.
Abstract:
There is disclosed a resin composition comprising:(a) 28 to 78% by weight of a polyamide resin,(b) 20 to 70% by weight of a polyphenylene ether resin,(c) 2 to 40% by weight of a block copolymer composed of an alkenyl aromatic polymer and a conjugated diene polymer wherein a content of an alkenyl aromatic polymer structure unit is 10 to 45% by weight and at least 50% of a conjugated diene polymer structure unit is hydrogenated and(d) at least one compound selected from the group consisting of .alpha.,.beta.-unsaturated dicarboxylic acid, an acid anhydride and derivatives thereof with an amount of 0.01 to 10 parts by weight based on 100 parts by weight of the sum of Components (a), (b) and (c),which has a specific dispersion state.The resin composition has excellent thermal stability and also good balance between impact strength, rigidity and high temperature rigidity with high degree.
Abstract:
A process of purifying maleic anhydride graft polyolefin comprising the steps of adding an aqueous solution of alkali initial hydroxide to a solution of maleic anhydride graft polyolefin containing unreacted maleic anhydride which is dissolved in an organic solvent at a temperature from 80.degree. C. to 160.degree. C., thereby precipitating maleic anhydride graft polyolefin particles to make a W/O emulsion; stirring the W/O emulsion while maintaining the temperature at a same temperature as above for less than 2 hours, thereby selectively forming the alkali metal salt of unreacted maleic anhydride; adding the aqueous solution of alkali metal hydroxide to the W/O emulsion to convert the W/O emulsion into an O/W emulsion; separating the maleic anhydride draft polyolefin particles, and washing the maleic anhydride graft polyolefin particles with water.